Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Cost of Revenue (2018 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Cost of Revenue for 7 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 49.13% year-over-year to $1.9 million, compared with a TTM value of $6.3 million through Dec 2025, up 52.34%, and an annual FY2025 reading of $6.3 million, up 52.34% over the prior year.
  • Cost of Revenue was $1.9 million for Q4 2025 at Agios Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.9 million in Q4 2025 and bottomed at $339000.0 in Q1 2022.
  • Average Cost of Revenue over 4 years is $943437.5, with a median of $708000.0 recorded in 2023.
  • The sharpest move saw Cost of Revenue surged 154.71% in 2023, then grew 13.18% in 2024.
  • Year by year, Cost of Revenue stood at $413000.0 in 2022, then skyrocketed by 41.89% to $586000.0 in 2023, then skyrocketed by 115.02% to $1.3 million in 2024, then skyrocketed by 49.13% to $1.9 million in 2025.
  • Business Quant data shows Cost of Revenue for AGIO at $1.9 million in Q4 2025, $1.7 million in Q3 2025, and $1.7 million in Q2 2025.